Is LEGN or SVRA more profitable?

Savara has a net margin of 0.00% compared to Legend Biotech's net margin of -0.02%. Legend Biotech's return on equity of -0.03% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Legend Biotech -0.02% -0.03% -0.02% Savara N/A -96.87% -74.22%

Does the media favor LEGN or SVRA?

In the previous week, Legend Biotech had 22 more articles in the media than Savara. MarketBeat recorded 35 mentions for Legend Biotech and 13 mentions for Savara. Savara's average media sentiment score of 0.94 beat Legend Biotech's score of -0.09 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 1 Very Positive mention(s) 4 Positive mention(s) 13 Neutral mention(s) 8 Negative mention(s) 2 Very Negative mention(s) Neutral Savara 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TNGX or SVRA more profitable?

Tango Therapeutics' return on equity of -30.34% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Tango Therapeutics N/A -30.34% -28.28% Savara N/A -96.87% -74.22%

Does the media favor TNGX or SVRA?

In the previous week, Tango Therapeutics had 20 more articles in the media than Savara. MarketBeat recorded 33 mentions for Tango Therapeutics and 13 mentions for Savara. Savara's average media sentiment score of 0.94 beat Tango Therapeutics' score of -0.02 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Savara 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is XENE or SVRA more profitable?

Xenon Pharmaceuticals' return on equity of -39.81% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Xenon Pharmaceuticals N/A -39.81% -37.98% Savara N/A -96.87% -74.22%

Does the media prefer XENE or SVRA?

In the previous week, Xenon Pharmaceuticals had 11 more articles in the media than Savara. MarketBeat recorded 24 mentions for Xenon Pharmaceuticals and 13 mentions for Savara. Savara's average media sentiment score of 0.94 beat Xenon Pharmaceuticals' score of 0.07 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Neutral Savara 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, PBLS or SVRA?

Parabilis Medicines is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Parabilis Medicines N/A N/A -$145.89M -$2.13 N/A Savara N/A N/A -$118.84M -$0.61 N/A

Is PBLS or SVRA more profitable?

Parabilis Medicines' return on equity of 0.00% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Parabilis Medicines N/A N/A N/A Savara N/A -96.87% -74.22%

Does the media prefer PBLS or SVRA?

In the previous week, Savara had 1 more articles in the media than Parabilis Medicines. MarketBeat recorded 13 mentions for Savara and 12 mentions for Parabilis Medicines. Savara's average media sentiment score of 0.94 beat Parabilis Medicines' score of 0.63 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Savara 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, VKTX or SVRA?

Savara is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viking Therapeutics N/A N/A -$359.64M -$5.40 N/A Savara N/A N/A -$118.84M -$0.61 N/A

Is VKTX or SVRA more profitable?

Savara's return on equity of -96.87% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Viking Therapeutics N/A -117.35% -88.87% Savara N/A -96.87% -74.22%

Does the media favor VKTX or SVRA?

In the previous week, Viking Therapeutics had 1 more articles in the media than Savara. MarketBeat recorded 14 mentions for Viking Therapeutics and 13 mentions for Savara. Savara's average media sentiment score of 0.94 beat Viking Therapeutics' score of 0.86 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Savara 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Savara (SVRA) Competitors

$4.64 -0.08 (-1.69%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$4.68 +0.04 (+0.97%)

As of 11/13/2026 07:44 PM Eastern

Compare

SVRA vs. LEGN, TNGX, XENE, PBLS, and VKTX

Should you buy Savara stock or one of its competitors? Savara's main competitors and comparable companies include Legend Biotech (LEGN), Tango Therapeutics (TNGX), Xenon Pharmaceuticals (XENE), Parabilis Medicines (PBLS), and Viking Therapeutics (VKTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Savara compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Savara (NASDAQ:SVRA) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Legend Biotech had 22 more articles in the media than Savara. MarketBeat recorded 35 mentions for Legend Biotech and 13 mentions for Savara. Savara's average media sentiment score of 0.94 beat Legend Biotech's score of -0.09 indicating that Savara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	1 Very Positive mention(s)	4 Positive mention(s)	13 Neutral mention(s)	8 Negative mention(s)	2 Very Negative mention(s)	Neutral
Savara	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Legend Biotech currently has a consensus price target of $50.85, suggesting a potential upside of 190.55%. Savara has a consensus price target of $10.29, suggesting a potential upside of 121.67%. Given Legend Biotech's higher probable upside, analysts plainly believe Legend Biotech is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Legend Biotech has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Savara has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Savara has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	3.30	-$296.80M	-$0.01	N/A
Savara	N/A	N/A	-$118.84M	-$0.61	N/A

70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by company insiders. Comparatively, 5.3% of Savara shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Savara has a net margin of 0.00% compared to Legend Biotech's net margin of -0.02%. Legend Biotech's return on equity of -0.03% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-0.02%	-0.03%	-0.02%
Savara	N/A	-96.87%	-74.22%

Summary

Legend Biotech beats Savara on 8 of the 15 factors compared between the two stocks.

How does Savara compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Savara (NASDAQ:SVRA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Tango Therapeutics presently has a consensus price target of $45.54, suggesting a potential upside of 78.58%. Savara has a consensus price target of $10.29, suggesting a potential upside of 121.67%. Given Savara's stronger consensus rating and higher possible upside, analysts clearly believe Savara is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	2 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.65
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Tango Therapeutics' return on equity of -30.34% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-30.34%	-28.28%
Savara	N/A	-96.87%	-74.22%

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Tango Therapeutics has higher revenue and earnings than Savara. Tango Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	69.27	-$101.59M	-$1.37	N/A
Savara	N/A	N/A	-$118.84M	-$0.61	N/A

In the previous week, Tango Therapeutics had 20 more articles in the media than Savara. MarketBeat recorded 33 mentions for Tango Therapeutics and 13 mentions for Savara. Savara's average media sentiment score of 0.94 beat Tango Therapeutics' score of -0.02 indicating that Savara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Savara	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Savara has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Summary

Tango Therapeutics beats Savara on 8 of the 14 factors compared between the two stocks.

How does Savara compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and Savara (NASDAQ:SVRA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 2.9% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Xenon Pharmaceuticals' return on equity of -39.81% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-39.81%	-37.98%
Savara	N/A	-96.87%	-74.22%

Xenon Pharmaceuticals currently has a consensus price target of $71.31, indicating a potential upside of 76.16%. Savara has a consensus price target of $10.29, indicating a potential upside of 121.67%. Given Savara's higher probable upside, analysts clearly believe Savara is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Xenon Pharmaceuticals had 11 more articles in the media than Savara. MarketBeat recorded 24 mentions for Xenon Pharmaceuticals and 13 mentions for Savara. Savara's average media sentiment score of 0.94 beat Xenon Pharmaceuticals' score of 0.07 indicating that Savara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Neutral
Savara	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xenon Pharmaceuticals has a beta of 0.11, suggesting that its stock price is 89% less volatile than the broader market. Comparatively, Savara has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

Savara has lower revenue, but higher earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	521.76	-$345.91M	-$4.70	N/A
Savara	N/A	N/A	-$118.84M	-$0.61	N/A

Summary

Xenon Pharmaceuticals beats Savara on 8 of the 15 factors compared between the two stocks.

How does Savara compare to Parabilis Medicines?

Parabilis Medicines (NASDAQ:PBLS) and Savara (NASDAQ:SVRA) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

87.9% of Savara shares are held by institutional investors. 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Parabilis Medicines' return on equity of 0.00% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Parabilis Medicines	N/A	N/A	N/A
Savara	N/A	-96.87%	-74.22%

In the previous week, Savara had 1 more articles in the media than Parabilis Medicines. MarketBeat recorded 13 mentions for Savara and 12 mentions for Parabilis Medicines. Savara's average media sentiment score of 0.94 beat Parabilis Medicines' score of 0.63 indicating that Savara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Parabilis Medicines presently has a consensus target price of $40.80, indicating a potential upside of 43.51%. Savara has a consensus target price of $10.29, indicating a potential upside of 121.67%. Given Savara's higher possible upside, analysts clearly believe Savara is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Parabilis Medicines is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parabilis Medicines	N/A	N/A	-$145.89M	-$2.13	N/A
Savara	N/A	N/A	-$118.84M	-$0.61	N/A

Summary

Savara beats Parabilis Medicines on 8 of the 12 factors compared between the two stocks.

How does Savara compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Savara (NASDAQ:SVRA) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by insiders. Comparatively, 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Savara's return on equity of -96.87% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-117.35%	-88.87%
Savara	N/A	-96.87%	-74.22%

Viking Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, Savara has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

In the previous week, Viking Therapeutics had 1 more articles in the media than Savara. MarketBeat recorded 14 mentions for Viking Therapeutics and 13 mentions for Savara. Savara's average media sentiment score of 0.94 beat Viking Therapeutics' score of 0.86 indicating that Savara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viking Therapeutics presently has a consensus target price of $93.36, indicating a potential upside of 219.52%. Savara has a consensus target price of $10.29, indicating a potential upside of 121.67%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Viking Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Savara is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$5.40	N/A
Savara	N/A	N/A	-$118.84M	-$0.61	N/A

Summary

Viking Therapeutics beats Savara on 7 of the 13 factors compared between the two stocks.

Get Savara News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SVRA vs. The Competition

Export

Metric	Savara	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.04B	$4.12B	$7.84B	$12.19B
Dividend Yield	N/A	3.62%	2.46%	4.53%
P/E Ratio	-7.61	25.73	34.71	28.44
Price / Sales	N/A	16.57	8.66	5.84
Price / Cash	N/A	26.37	21.93	22.49
Price / Book	9.47	4.00	4.35	3.76
Net Income	-$118.84M	-$22.78M	$3.51B	$390.55M
7 Day Performance	-3.93%	-2.85%	-1.49%	-0.33%
1 Month Performance	-2.11%	-3.75%	-2.55%	-4.82%
1 Year Performance	7.91%	-1.56%	0.92%	-5.83%

Savara Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SVRA Savara	2.6697 of 5 stars	$4.64 -1.7%	$10.29 +121.7%	N/A	$1.04B	N/A	N/A	70	News Coverage Earnings Report Analyst Forecast Options Volume
LEGN Legend Biotech	3.2752 of 5 stars	$21.13 -13.0%	$54.69 +158.8%	N/A	$4.09B	$1.03B	N/A	2,965	News Coverage Earnings Report Analyst Forecast
TNGX Tango Therapeutics	2.5966 of 5 stars	$23.73 +4.4%	$44.54 +87.7%	N/A	$4.01B	$62.38M	N/A	137	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision
XENE Xenon Pharmaceuticals	3.382 of 5 stars	$40.84 +1.0%	$71.31 +74.6%	N/A	$3.95B	$7.50M	N/A	364	Trending News Earnings Report Analyst Revision
PBLS Parabilis Medicines	2.8965 of 5 stars	$31.32 +3.1%	$40.80 +30.3%	N/A	$3.87B	N/A	N/A	145	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SVRA) was last updated on 11/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Savara (SVRA) Competitors

SVRA vs. LEGN, TNGX, XENE, PBLS, and VKTX

How does Savara compare to Legend Biotech?

Summary

How does Savara compare to Tango Therapeutics?

Summary

How does Savara compare to Xenon Pharmaceuticals?

Summary

How does Savara compare to Parabilis Medicines?

Summary

How does Savara compare to Viking Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA vs. The Competition

Savara Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Savara (SVRA) Competitors

SVRA vs. LEGN, TNGX, XENE, PBLS, and VKTX

How does Savara compare to Legend Biotech?

Does the media favor LEGN or SVRA?

Do analysts rate LEGN or SVRA?

Which has more volatility and risk, LEGN or SVRA?

Which has better valuation and earnings, LEGN or SVRA?

Do insiders and institutionals hold more shares of LEGN or SVRA?

Is LEGN or SVRA more profitable?

Summary

How does Savara compare to Tango Therapeutics?

Do analysts rate TNGX or SVRA?

Is TNGX or SVRA more profitable?

Do insiders & institutionals hold more shares of TNGX or SVRA?

Which has higher earnings & valuation, TNGX or SVRA?

Does the media favor TNGX or SVRA?

Which has more risk & volatility, TNGX or SVRA?

Summary

How does Savara compare to Xenon Pharmaceuticals?

Do institutionals and insiders believe in XENE or SVRA?

Is XENE or SVRA more profitable?

Do analysts prefer XENE or SVRA?

Does the media prefer XENE or SVRA?

Which has more volatility and risk, XENE or SVRA?

Which has better earnings & valuation, XENE or SVRA?

Summary

How does Savara compare to Parabilis Medicines?

Do insiders and institutionals believe in PBLS or SVRA?

Is PBLS or SVRA more profitable?

Does the media prefer PBLS or SVRA?

Do analysts rate PBLS or SVRA?

Which has preferable valuation and earnings, PBLS or SVRA?

Summary

How does Savara compare to Viking Therapeutics?

Do insiders and institutionals believe in VKTX or SVRA?

Is VKTX or SVRA more profitable?

Which has more risk and volatility, VKTX or SVRA?

Does the media favor VKTX or SVRA?

Do analysts rate VKTX or SVRA?

Which has preferable valuation and earnings, VKTX or SVRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA vs. The Competition

Savara Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools